Noevir Holdings (TSE:4928) just rolled out a higher year-end dividend while confirming plans to maintain that level next year. These actions, along with updated earnings guidance, highlight its commitment to shareholder returns.

See our latest analysis for Noevir Holdings.

Noevir Holdings’ announcement of a higher dividend and fresh earnings guidance has coincided with a recent pick-up in share price momentum. The stock has rebounded 3.8% over the past month. That said, its one-year total shareholder return is down just under 2%, and longer-term performance has lagged, but the new shareholder-friendly moves could shape sentiment going forward.

If you’re inspired by dividend growth and resilient business models, now’s the perfect opportunity to explore fast growing stocks with high insider ownership.

With a modest share price rebound but still undervalued by some analyst measures, the question remains: is this a genuine buying opportunity for Noevir Holdings, or are markets already factoring in all the growth ahead?

Noevir Holdings trades with a price-to-earnings ratio of 19.7x, noticeably below its industry peer average of 36x. At the most recent close of ¥4,625, this might suggest the stock is attractively valued relative to its competitors.

The price-to-earnings (P/E) ratio compares a company's current share price to its per-share earnings. For consumer and personal products businesses like Noevir Holdings, this multiple gives investors a quick sense of how the market values the company's profitability versus sector norms.

Such a lower P/E can imply the market expects slower profit growth ahead or is discounting specific risks. However, compared to the JP Personal Products industry’s average P/E of 23.8x, Noevir Holdings is priced at a noticeable discount. Against its fair price-to-earnings ratio estimate of 18.9x, the current P/E appears only slightly above that level, potentially leaving room for re-rating if growth or sentiment improves further.

Explore the SWS fair ratio for Noevir Holdings

Result: Price-to-Earnings of 19.7x (UNDERVALUED)

However, slower annual revenue and net income growth, along with muted long-term returns, could limit upside as markets weigh renewal of optimism.

Find out about the key risks to this Noevir Holdings narrative.

Taking a look from a different angle, the SWS DCF model suggests that Noevir Holdings is actually trading about 6% below its estimated fair value. This implies the market might be underestimating the company's true worth. Could this gap indicate untapped potential, or is the discount justified?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Noevir Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 920 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

If you have your own take on Noevir Holdings or enjoy digging into the numbers firsthand, you can quickly build your own narrative in just a few minutes. Do it your way.

A great starting point for your Noevir Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Don’t let great ideas pass you by. The market is filled with hidden gems, and the right tools help you spot them faster than the crowd.

Catch up on companies paying attractive yields by checking out 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">these 16 dividend stocks with yields > 3%, which offers yields over 3% and has the potential to bolster portfolios with steady income.

Target next-generation innovation by reviewing these 25 AI penny stocks, which highlights stocks with strong artificial intelligence growth potential and provides a tech-forward edge for your investments.

Capitalize on value by seeing these 920 undervalued stocks based on cash flows and consider acting while these stocks remain below their intrinsic worth.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include 4928.T.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com